

---

**School of Health and Rehabilitation Sciences**  
**NHMRC Centre of Clinical Research Excellence**  
**on Spinal Pain, Injury and Health**

**HONORARY SENIOR RESEARCH FELLOW**

Hugo Massé-Alarie PhD PT

The University of Queensland  
Brisbane Qld 4072 Australia  
Email:

[h.massealarie@uq.edu.au](mailto:h.massealarie@uq.edu.au)

[hugo.masse-alarie@fmed.ulaval.ca](mailto:hugo.masse-alarie@fmed.ulaval.ca)

26 avril, 2021

**ISSLS Research Committee members**

Institute of Clinical Sciences,  
University of Gothenburg  
PO Box 426  
SE 405 30 Gothenburg, Sweden

**RE : Final report ISSLS Research Grant sponsored by Taisho Pharmaceutical**

To whom it may concern,

First of all, we would like to express our gratitude to ISSLS and particularly to Taisho Pharmaceutical for funding our study entitled "*The role of neuroimmune response on sensorimotor function in different classes of chronic low back pain*". The grant will provide the opportunity to address important questions about the impact of different classes of chronic low back pain on the function of the brain and to provide preliminary data that will be used to prepare a proposal that will be submitted to a major funding organisation.

The ISSLS Taisho Pharmaceutical grant allowed to recruit 8 participants with chronic low back pain (CLBP) and 3 healthy and pain-free controls. We expect to test 6 more participants in May 2021 (1 CLBP and 5 controls). One of the aims of the study was to stratify participants with CLBP using the pain mechanism-based classification (nociceptive, nociplastic or neuropathic pain) and compare if different classes of LBP present with different glial activation in sensory and motor brain areas. So far, we were not


able to recruit pure neuropathic CLBP. Thus, 5 participants with nociplastic CLBP and 4 participants with nociceptive CLBP, and 8 controls were recruited and tested.

Some preliminary analyses have been undertaken although we are still waiting to complete the recruitment to finalise them. Please consider that preliminary results summarized in this report are not final and results may change considering the very small sample size. In the CLBP group only, glial activation was larger in the primary motor cortex (M1) back area compared to the M1 area of the leg or of the hand. This trend was not present in controls. Considering the small number of participants, we have not compared our results between classes of CLBP yet. Analysis of the transcranial magnetic stimulation (TMS) and quantitative sensory testing (QST) data are still being analysed.

The pandemic context delayed data collection and subsequent analysis. Indeed, it was not possible to travel inter-state in Australia for much of the last year. Indeed, PET/MRI data collection is done at Monash Biomedical Imaging center (MBI) laboratory in Melbourne, Victoria, whereas Muath Shraim, the graduate student dedicated to this project, is located at The University of Queensland, in Brisbane, Queensland.

Again, we are grateful to ISSLS and Taisho Pharmaceutical for funding the research and a proposal to major funding bodies will be prepared using our preliminary results. Results have the potential to understand better how different clinical representations of pain influence brain function and provide important insights to improve management of individuals presenting different classes of CLBP.

Sincerely,

A handwritten signature in blue ink, reading "Hugo Massé-Alarie". The signature is fluid and cursive, with the first name "Hugo" being more prominent and the last name "Massé-Alarie" following in a similar style.

Hugo Massé-Alarie PhD PT  
*Honorary senior research fellow*  
NHMRC Centre of Clinical Research Excellence in Spinal Pain, Injury & Health,  
School of Health & Rehabilitation Sciences, The University of Queensland,  
QLD, 4072, Australia